Nurix Therapeutics Inc. (NRIX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Does Nurix Therapeutics (NRIX) Have the Potential to Rally 85.84% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 85.8% in Nurix Therapeutics (NRIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide
Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $0.67 per share a year ago.
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.75 per share a year ago.
Nurix Therapeutics: Why This Company Could Double In Value?
Nurix Therapeutics is positioned for a breakthrough in CLL with NX-5948, demonstrating strong efficacy in post-Pirtobrutinib settings. Phase 1 data showed an 83% response rate at 600mg and 22.1 months of progression-free survival, enabling direct advancement to phase 3 trials. NRIX holds $680M in cash, supporting R&D through 2027-2028 and minimizing dilution risk for shareholders.
Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nurix Therapeutics, Inc. (NRIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nurix Therapeutics: Clinical Wins Offer Asymmetric Upside
Nurix Therapeutics offers a compelling risk/reward profile, driven by bexobrutideg's superior efficacy in B-cell malignancies versus current therapies. NRIX's strong cash position—over $650 million—funds operations through 2028, supporting aggressive R&D and pivotal trial advancement. Bexobrutideg's unique BTK degradation mechanism delivers longer progression-free survival and CNS activity, addressing critical unmet needs in relapsed/refractory patients.
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical Data and Pipeline Update for BTK Degrader Program Bexobrutideg Transcript
Nurix Therapeutics, Inc. (NRIX) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs Transcript
Nurix Therapeutics, Inc. (NASDAQ:NRIX ) Discusses Clinical and Preclinical Updates on BTK, STAT6, and IRAK4 Degrader Programs October 22, 2025 8:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Paula O'Connor - Chief Medical Officer Gwenn Hansen - Chief Scientific Officer Johannes Van Houte - Chief Financial Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Gil Blum - Needham & Company, LLC, Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Joseph Catanzaro Brian Abrahams - RBC Capital Markets, Research Division Sudan Loganathan - Stephens Inc., Research Division Alexander Barenklau - Barclays Bank PLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Arthur Sands CEO, President & Director Good morning, and welcome to the Nurix Therapeutics Conference Call.
